文献速递脑血管病

间歇性低氧预处理通过PF4依赖性旁分泌机制保护小鼠缺血性脑损伤

Intermittent Hypoxia Preconditioning Protects Against Ischemic Brain Injury in Mice via a PF4-Dependent Paracrine Mechanism.
PubMed 文献 · Stroke · 2026-01-22

研究用492只C57BL/6J小鼠验证间歇性低氧(IH)预处理的神经保护是否由外周旁分泌介导。2周IH方案(13% O2,5分钟间隔,10周期/日)生成IH血浆(IHP),静脉给药可减少远端大脑中动脉闭塞后梗死体积并改善感觉运动功能。蛋白质组学鉴定PF4为关键旁分泌介质,PF4免疫清除取消保护,重组PF4可复制获益并保护血脑屏障。

要点

  • 系统性给予IHP可减轻远端大脑中动脉闭塞后的急性脑损伤。
  • 卒中后给予IHP对短暂性大脑中动脉闭塞有急性和持续神经保护。
  • PF4是IH神经保护的关键旁分泌介质,重组PF4可复制其获益。

核心结论

  • PF4被确定为IH诱导神经保护的关键旁分泌介质,支持IHP和PF4干预对缺血性卒中的治疗潜力。

研究设计与样本

  • 共使用492只C57BL/6J小鼠:434只年轻雄性(2-3月龄)、29只年轻雌性(2-3月龄)和29只老年雄性(18月龄)。
  • 采用2周IH方案(13% O2,5分钟间隔,10周期/日)生成IH血浆(IHP)。
  • IHP或常氧血浆(100 μL/次注射)每3天静脉给药一次(共6剂)于远端大脑中动脉闭塞前。
  • 治疗评估中,血浆在远端大脑中动脉闭塞后或60分钟短暂大脑中动脉闭塞后每日给药3天,长期研究中每3天追加6剂。
  • 通过蛋白质组学鉴定候选循环介质,并用抗体介导的清除和重组蛋白补充验证。

主要发现

  • 系统性IHP给药保护远端大脑中动脉闭塞后的急性脑损伤,减少梗死体积并改善感觉运动表现。
  • 卒中后给予IHP在短暂大脑中动脉闭塞中提供急性和持续神经保护,改善感觉运动和认知恢复并减少卒中后长达4周的脑萎缩,但在远端大脑中动脉闭塞中无此效果。
  • 蛋白质组学鉴定出120种IH上调的血浆蛋白,其中PF4(血小板因子4)是一种具有强神经保护特性的细胞因子。
  • PF4免疫清除消除了IHP诱导的神经保护,而重组PF4在不同性别和年龄中复制了这些获益。
  • PF4治疗保护短暂大脑中动脉闭塞后的血脑屏障破坏,减轻IgG外渗和内皮闭锁小带蛋白-1表达丢失。

临床怎么用

  • IHP和PF4干预可能成为缺血性卒中的治疗策略,但需进一步临床转化研究。

局限性

  • 研究仅在小鼠中进行,结论外推到人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intermittent hypoxia (IH) preconditioning enhances brain resilience, thereby protecting against subsequent ischemic injury, yet its precise mechanisms remain elusive. We tested the novel hypothesis that peripheral paracrine mechanisms mediate IH-induced neuroprotection. METHODS: A total of 492 C57BL/6J mice were used: 434 young males (2-3 months), 29 young females (2-3 months), and 29 aged males (18 months). A 2-week IH regimen (13% O2, 5-minute intervals, 10 cycles/d) was applied to generate IH-derived plasma (IHP). To test the hypothesis, IHP or normoxic plasma (100 μL/injection) was intravenously administered every 3 days (6 doses total) before distal middle cerebral artery occlusion. For therapeutic evaluation, plasma was administered daily for 3 days after distal middle cerebral artery occlusion or 60-minute transient middle cerebral artery occlusion, followed by additional doses every 3 days for 6 doses in long-term transient middle cerebral artery occlusion studies. Infarct volume and neurological deficits were primary outcomes. Candidate circulating mediators were identified via proteomics and validated by antibody-mediated depletion and recombinant protein supplementation. Blood-brain barrier integrity was further examined. RESULTS: Systemic IHP administration protected against acute brain injury after distal middle cerebral artery occlusion, reducing infarct volume and improving sensorimotor performance. Poststroke administration of IHP conferred acute and sustained neuroprotection in transient middle cerebral artery occlusion, but not distal middle cerebral artery occlusion, improving sensorimotor and cognitive recovery and reducing brain atrophy up to 4 weeks after stroke. Proteomic profiling identified 120 IH-upregulated plasma proteins, notably PF4 (platelet factor 4), a cytokine with potent neuroprotective properties. PF4 immunodepletion abolished IHP-induced neuroprotection, whereas recombinant PF4 replicated these benefits across sex and age. Furthermore, PF4 treatment protected against blood-brain barrier disruption after transient middle cerebral artery occlusion, attenuating IgG extravasation and loss of endothelial expression of zonula occludens-1. CONCLUSIONS: These findings identify PF4 as a key paracrine mediator of IH-induced neuroprotection and support the therapeutic potential of both IHP and PF4-based interventions for ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Liu Y, Gu Y, Jin F, et al. Intermittent Hypoxia Preconditioning Protects Against Ischemic Brain Injury in Mice via a PF4-Dependent Paracrine Mechanism. Stroke. 2026. PMID: 41568448. doi:10.1161/STROKEAHA.125.052213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。